Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$19.73
-4.7%
$18.23
$14.53
▼
$21.40
$7.07B0.52490,182 shs234,967 shs
PepGen, Inc. stock logo
PEPG
PepGen
$3.83
-2.6%
$2.86
$1.31
▼
$7.80
$263.53M2.021.69 million shs760,157 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-1.12%-2.11%+22.38%+19.97%+41.41%
PepGen, Inc. stock logo
PEPG
PepGen
+2.61%-22.02%+36.93%+25.16%-28.93%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$19.73
-4.7%
$18.23
$14.53
▼
$21.40
$7.07B0.52490,182 shs234,967 shs
PepGen, Inc. stock logo
PEPG
PepGen
$3.83
-2.6%
$2.86
$1.31
▼
$7.80
$263.53M2.021.69 million shs760,157 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-1.12%-2.11%+22.38%+19.97%+41.41%
PepGen, Inc. stock logo
PEPG
PepGen
+2.61%-22.02%+36.93%+25.16%-28.93%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.40
Hold$21.086.88% Upside
PepGen, Inc. stock logo
PEPG
PepGen
2.57
Moderate Buy$11.40197.88% Upside

Current Analyst Ratings Breakdown

Latest BLCO and PEPG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Reiterated RatingSell (D-)
11/17/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Boost Price TargetOverweight$24.00 ➝ $27.00
11/13/2026
PepGen, Inc. stock logo
PEPG
PepGen
Boost Price TargetBuy$7.00 ➝ $15.00
11/11/2026
PepGen, Inc. stock logo
PEPG
PepGen
Boost Price TargetOutperform$4.00 ➝ $10.00
11/10/2026
PepGen, Inc. stock logo
PEPG
PepGen
UpgradeUnderperform ➝ Neutral$2.50 ➝ $6.00
11/2/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
DowngradeBuy ➝ Neutral$21.00 ➝ $22.00
10/30/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
UpgradeHold ➝ Strong-Buy
10/29/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Reiterated RatingHold$20.00
10/29/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Boost Price TargetBuy$21.00 ➝ $23.00
10/29/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Boost Price TargetNeutral$16.00 ➝ $22.00
10/29/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Boost Price TargetOutperform$21.00 ➝ $23.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$5.10B1.38$1.57 per share12.56$18.18 per share1.09
PepGen, Inc. stock logo
PEPG
PepGen
N/AN/AN/AN/A$1.49 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$360M-$0.31N/A16.860.55-2.05%5.01%2.34%N/A
PepGen, Inc. stock logo
PEPG
PepGen
-$89.65M-$1.07N/AN/AN/AN/A-58.18%-48.92%N/A

Latest BLCO and PEPG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
PepGen, Inc. stock logo
PEPG
PepGen
-$0.2707-$0.28-$0.0093-$0.28N/AN/A
10/28/2026Q3 2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.2145$0.34+$0.1255$0.09$1.37 billion$1.38 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
PepGen, Inc. stock logo
PEPG
PepGen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.78
1.56
1.04
PepGen, Inc. stock logo
PEPG
PepGen
N/A
8.70
8.70

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
PepGen, Inc. stock logo
PEPG
PepGen
58.01%

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
1.45%
PepGen, Inc. stock logo
PEPG
PepGen
1.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,000358.08 million352.89 millionOptionable
PepGen, Inc. stock logo
PEPG
PepGen
5369.26 million68.36 millionOptionable

Recent News About These Companies

What is HC Wainwright's Estimate for PepGen FY2026 Earnings?
FY2026 Earnings Estimate for PepGen Issued By HC Wainwright
PepGen's Myotonic Dystrophy Drug PGN-EDODM1
PepGen (NASDAQ:PEPG) Price Target Raised to $15.00
PepGen (NASDAQ:PEPG) Rating Lowered to Sell at Wall Street Zen
PepGen (NASDAQ:PEPG) Cut to Sell at Wall Street Zen
PepGen (NASDAQ:PEPG) Price Target Raised to $10.00
PepGen prices $125 million public offering at $5 per share
PepGen Announces Pricing of $125 Million Public Offering
PepGen’s stock skyrockets on record-breaking DM1 trial data
PepGen (NASDAQ:PEPG) Stock Price Target Raised at Wedbush
PepGen Stock Soars 129% Despite Wider Q3 Loss

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$19.73 -0.96 (-4.65%)
As of 10:50 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

PepGen stock logo

PepGen NASDAQ:PEPG

$3.83 -0.10 (-2.62%)
As of 10:50 AM Eastern
This is a fair market value price provided by Massive. Learn more.

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.